A naukri.com initiative
Bioengineer
1w
334
Image Credit: Bioengineer
Tracking Tumor-Informed Circulating Tumor DNA Following Comprehensive Genomic Profiling
- Circulating tumor DNA (ctDNA) can be utilized effectively to predict cancer relapse and treatment response, revealing new hope for advanced cancer patients.
- Combining ctDNA measurements with the comprehensive genomic profiling (CGP) can greatly enhance personalized cancer treatment strategies.
- Researchers have found that the novel digital PCR (dPCR) technique known as the Off The Shelf-assay (OTS-Assay) offers a powerful method to track tumor dynamics in patients.
- The clinical validity of the OTS-Assay was rigorously tested, focusing on key outcomes like early relapse prediction, treatment response evaluation, and confirmation of no relapse or tumor regrowth. The monitoring process was conducted on 11 patients, of which an impressive 90.9% achieved at least one validated outcome.
- This study brings significant insights for the majority of patients who do not receive the recommended treatments despite undergoing CGP.
- Moreover, the ability to utilize ctDNA monitoring through the OTS-Assay offers an essential tool for effective cancer management, allowing patients to track their disease’s evolution without necessarily relying on conventional therapeutic options.
- The findings from this research contribute to the ongoing evolution of personalized medicine in oncology.
- However, researchers recognize that further studies are necessary to establish the OTS-Assay’s reliability across various cancer types.
- With patient-focused innovations like the OTS-Assay, there’s an optimistic horizon for improving therapeutic strategies and enhancing the quality of life for countless cancer patients globally.
- Researchers and healthcare providers must collaborate to simplify and streamline the processes, enabling widespread access to such advanced monitoring techniques.
Read Full Article
20 Likes
For uninterrupted reading, download the app